HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Struglics Selected Research

Knee Injuries (Knee Injury)

1/2022The alarmins high mobility group box protein 1 and S100A8/A9 display different inflammatory profiles after acute knee injury.
1/2018Dickkopf-related protein 1 and gremlin 1 show different response than frizzled-related protein in human synovial fluid following knee injury and in patients with osteoarthritis.
1/2017Concentrations of synovial fluid biomarkers and the prediction of knee osteoarthritis 16 years after anterior cruciate ligament injury.
11/2015Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy.
9/2015Type II collagen C2C epitope in human synovial fluid and serum after knee injury--associations with molecular and structural markers of injury.
2/2014An ARGS-aggrecan assay for analysis in blood and synovial fluid.
11/2012Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis.
8/2011Human aggrecanase generated synovial fluid fragment levels are elevated directly after knee injuries due to proteolysis both in the inter globular and chondroitin sulfate domains.
4/2009Western blot quantification of aggrecan fragments in human synovial fluid indicates differences in fragment patterns between joint diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


A Struglics Research Topics

Disease

9Knee Injuries (Knee Injury)
01/2022 - 04/2009
7Osteoarthritis
01/2022 - 02/2006
3Inflammation (Inflammations)
01/2022 - 01/2017
3Wounds and Injuries (Trauma)
01/2022 - 08/2011
3Knee Osteoarthritis
01/2017 - 05/2012
2Anterior Cruciate Ligament Injuries
01/2020 - 01/2017
2Joint Diseases (Joint Disease)
04/2009 - 07/2006
1Synovitis
01/2020
1Rupture
10/2018
1Osteophyte
11/2015
1Hemarthrosis
11/2012
1Arthritis (Polyarthritis)
04/2009

Drug/Important Bio-Agent (IBA)

8Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2006
7Aggrecans (Aggrecan)IBA
01/2017 - 02/2006
4CytokinesIBA
01/2020 - 11/2012
4aggrecanaseIBA
05/2012 - 02/2006
2Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2018
1AlarminsIBA
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1HMGB1 Protein (HMG1)IBA
01/2022
1Cartilage Oligomeric Matrix ProteinIBA
10/2018
1Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA
01/2018
1WD repeat containing planar cell polarity effectorIBA
01/2018
1Tissue Inhibitor of Metalloproteinase-1IBA
01/2017
1InterleukinsIBA
11/2015
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2015
1Interleukin-6 (Interleukin 6)IBA
11/2015
1Collagen Type II (Type II Collagen)IBA
09/2015
1EpitopesIBA
09/2015
1GlycosaminoglycansIBA
05/2012
1Immunoglobulin D (IgD)IBA
08/2011
1Chondroitin Sulfates (Chondroitin Sulfate)IBA
08/2011
1cesium chloride (CsCl)IBA
04/2009
1Matrix Metalloproteinases (MMPs)IBA
02/2006

Therapy/Procedure

2Meniscectomy
11/2015 - 05/2012